에 대한 최신 뉴스 Exact Sciences (NASDAQ:EXAS) 주식

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Large Cap

News

Movers

ARWR

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

SRPT

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

Biotech

Earnings

After-Hours Center

이그젝트 사이언스(NASDAQ:EXAS) 주가는 화요일(5일) 장 마감 이후 3분기 실적을 발표한 후 하락하고 있다. 실적 관련해 자세한 내용을 살펴보자. 실적 세부 사항: 이그젝트 사이언스의 분기 기준 GAAP 주당순손실은 21센트로 애널리스트 컨센서스 예상치 주당순손실 20센트를 하회했다. 분기 매출은 7억 900만 달러로 컨센서스 예상치 7억 1,766만 달러에 미치지 못했다. 

이그젝트 사이언스, 부진한 3분기 실적 발표 이후 30% 가까이 급락, 연간 지침 예상치 하회

$BTC

AVGO

BNTX

CHWY

FSLR

MSTR

ORCL

ROKU

SMMT

WOOF

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식은 회사가 $2억 3,500만의 순수익을 올렸다고 발표한 후 98.32% 급등했다.

츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) underwent analysis by 19 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">14</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.63, a high estimate of $95.00, and a low estimate of $60.00. This current average has decreased by 5.94% from the previous average price target of $78.28. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655212_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Exact Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Nowark</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exact Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exact Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.78%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exact Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exact Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 19 Analyst Projections For Exact Sciences

Barclays analyst Luke Sergott initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight rating and announces Price Target of $70.

Price Target

Initiation

Barclays Initiates Coverage On Exact Sciences with Overweight Rating, Announces Price Target of $70

Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients.
In addition to the data shared at ASCO GI, Oncodetect achieved its primary endpoint in the Beta-CORRECT study.&nbsp;
&nbsp;
&nbsp;

Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer

Exact Sciences Plans To Present 11 Abstracts At ASCO GI Meeting In San Francisco

On Sunday, Exact Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.74 billion</a>.
For 2024, the company expects screening revenue of $2.104 billion, up 13%, and Precision Oncology revenue of $655 million, up 4%.
The cancer detection company expects fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, compared to the consensus of $694.80 million.
The preliminary sales include screening revenue of $553 million and Precision Oncology revenue of $161 million.
The company plans to launch three new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42936301/exact-sciences-announces-preliminary-fourth-quarter-2024-results" rel="noreferrer noopener">cancer tests in 2025</a>:
<ul>
<li>Cologuard Plus, next-generation colorectal cancer screening test.</li>
<li>Oncodetect, a molecular residual disease test.</li>
<li>Cancerguard, multi-cancer screening test.</li>
</ul>
Goldman Sachs analyst Matthew Sykes highlights colorectal cancer (CRC) screening and multi-cancer early detection (MCED) as key risk areas in a competitive market.
The analyst writes that Exact Sciences stands out due to its established business and the higher accuracy of its stool-based DNA test compared to blood-based alternatives. However, the company's MCED test is still years away from being market-ready.
Sykes believes success in CRC screening could provide Exact Sciences with a major research and development edge, enabling a faster MCED launch thanks to its experienced team and existing infrastructure. On the other hand, failing to launch an MCED test within 3-4 years could undermine the firm's investment outlook.
William Blair analyst Andrew Brackmann suggests that even a slight revenue beat, like this one, is unlikely to shift sentiment in the short term. Key updates on Cologuard's 2025 reacceleration and progress toward profitability likely won't surface until after the first quarter.
Brackmann anticipates this will remain the case but looks forward to insights on 2025 expectations and new product launches, including the company's MCED test, set to debut this year.
The long-term outlook remains strong, with shares trading at an attractive 4.1 times 2025 revenue. William Blair maintains <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">its Outperform rating</a>.
Price Action: EXAS stock is down 1.61% at $55.59 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42953261/nvidia-broadcom-and-marvell-positioned-for-growth-as-ai-demand-drives-semiconductor-momentum" target="_blank" rel="noreferrer noopener">Nvidia, Broadcom, Marvell Positioned For Growth As AI Demand Drives Semiconductor Momentum</a></li>
</ul>

Analyst Color

Guidance

Health Care

Trading Ideas

General

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

Benchmark analyst Bruce Jackson reiterates Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and maintains $65 price target.

Reiteration

Benchmark Reiterates Buy on Exact Sciences, Maintains $65 Price Target

Expects total fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 millionAnticipates total
<ul>
<li>Expects total fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million</li>
<li>Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023</li>
<li>Plans to launch three new cancer tests in 2025: Cologuard PlusTM, next-generation colorectal cancer screening test, OncodetectTM, molecular residual disease test, and CancerguardTM, multi-cancer screening test</li>
</ul>

Reported Earlier, Exact Sciences Reports Preliminary 2024 Results: Expects $2.76B In Annual Revenue (+10% YoY) And $713M In Q4 Revenue (+10% YoY)

Exact Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NYSE">EXAS</a>) short percent of float has fallen 5.27% since its last report. The company recently reported that it has 11.20 million shares sold short, which is 6.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Exact Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735668017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exact Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Exact Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Exact Sciences's peer group average for short interest as a percentage of float is 4.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(EXAS) - Analyzing Exact Sciences's Short Interest

B of A Securities analyst Derik De Bruin maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $75 to $72.

B of A Securities Maintains Buy on Exact Sciences, Lowers Price Target to $72

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares jumped 22.06% after securing a<a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener"> $6.6 billion DOE loan commitment</a>.</li>
<li>Rocket Lab USA, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock surged 21.73% after it secured a $23.9 million CHIPS Act grant to enhance its <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">semiconductor operations in New Mexico</a>.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock upped 20.67% after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) for <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">multiple clinical and preclinical siRNA programs</a>.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock increased 16.98%. The Centers for Medicare &amp; Medicaid Services posted final payment determinations for its <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025 Clinical Laboratory Fee Schedule</a>.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares rose 16.29%. Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">transformative impact on the software sector</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares upped 14.13%. Citigroup analysts raised the<a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast on the stock</a>.</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) <a href="https://www.benzinga.com//node/42197195" target="_blank" rel="noreferrer noopener">shares surged 12.58%</a> last week.</li>
<li>Ralph Lauren Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) stock gained 11.72% last week.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) stock was up 11.41% after the company reported better-than-expected Q1 sales results.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) stock increased 12.18%. Citigroup analysts raised the <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by rblfmr via Shutterstock

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

Editor&#8217;s note: The headline of this story was updated to correct an error related to the reported day of the week.
On Monday, the Centers for Medicare &amp; Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Included was a final decision related to CMS pricing for Exact Sciences Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus, a second-generation test that received FDA <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">approval in October</a>.
William Blair writes that the <a target="_blank" href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings" rel="noreferrer noopener">determinations</a> effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a>
The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.
The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).
This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.
The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.
From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair&#8217;s estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42177702/exact-sciences-advances-breast-cancer-care-with-the-oncotype-dx-test-and-genomic-profiling-researc" rel="noreferrer noopener">scheduled next month</a>.
Price Action: EXAS stock is up 7.60% at $59.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Equities

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

19 analysts have shared their evaluations of Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.37, a high estimate of $95.00, and a low estimate of $60.00. A 3.95% drop is evident in the current average compared to the previous average price target of $78.47. 
<img src="https://www.benzinga.com/files/images/story/2024/1732644078_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exact Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Nowark</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Exact Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Exact Sciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Exact Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.78% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.4%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 19 Analyst Ratings Have To Say About Exact Sciences

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $82 to $86.

TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $86

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $65 to $75.

BTIG Maintains Buy on Exact Sciences, Raises Price Target to $75

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose sharply during Tuesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance with its <a href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more">midpoint above estimates.</a>
Smucker shares surged 6.2% to $120.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 59% to $7.55 after the company reported better-than-expected third-quarter sales results.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) gained 30.2% to $18.76 after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) surged 22.8% to $4.1750 after the company announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) gained 20.3% to $64.32 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its midpoint above estimates.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 18.1% to $22.17 after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.</li>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares rose 15% to $25.65.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) gained 13.8% to $1.8450.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 12.6% to $2.1850.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) surged 12.2% to $4.77. POET Technologies recently announced plans to expand its capacity.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares gained 9.1% to $125.10 after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) gained 8% to $99.21 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) surged 7.8% to $59.45. The company announced it will present 10 abstracts at SABCS.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) surged 7.4% to $192.62 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 7.3% to $25.82.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 5.8% to $8.94. UBS analyst Jay Sole upgraded Hanesbrands from Neutral to Buy and raised the price target from $9 to $11.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42190113/starbucks-to-rally-around-13-here-are-10-top-analyst-forecasts-for-tuesday">Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Intraday Update

Markets

EMBC

HSAI

NGNE

POET

SGMO

SMRT

SMTC

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

WIIM

Exact Sciences shares are trading higher. The company announced it will present 10 abstracts at SABCS.

U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.&#8217;s largest trading partners &#8211; Canada and Mexico &#8211; with tariffs.
The Dollar Index strengthened and was hovering around the 107 level. Expectations of a further 25 basis point rate cut in December have fallen to just 59% now, down from 75% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.09%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.07%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.26%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.06% to $597.87 and the Invesco QQQ ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>) rose 0.04% to $506.80, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The Dow Jones closed higher by around 440 points to 44,736.57 on Monday. The S&amp;P 500 rose 0.30% to 5,987.37, while the Nasdaq Composite rose 0.27% to close at 19,054.84 during Monday&#8217;s session.
On the economic data front, the Chicago Fed National Activity Index fell to -0.40 in October compared to -0.27 in the previous month and versus market estimates of -0.20.
The Dallas Fed&#8217;s Texas manufacturing activity index rose to -2.7 in November compared to a reading of -3 in the previous month and versus market estimates of -2.4.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, materials, and consumer discretionary stocks recording the biggest gains on Monday.
However, energy and information technology stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.27%</td>
<td>19,054.84</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
<td>5,987.37</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.99%</td>
<td>44,736.57</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.47%</td>
<td>2,442.03</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
&#8220;Equity markets continue to display remarkable strength. The S&amp;P 500 and other major indices are flirting with or surpassing all-time highs. The breadth of the rally is particularly noteworthy, with a growing number of stocks hitting 52-week highs,&#8221; said Jeremy Siegel, a senior economist <a href="https://resources.wisdomtree.com/weekly-siegel-commentary/">at</a> WisdomTree.
&#8220;This breadth is a key signal of market health, as it indicates a robust and inclusive rally rather than one concentrated in a few mega-cap names,&#8221; he added.
Analysts at BlackRock <a href="https://www.blackrock.com/us/individual/insights/blackrock-investment-institute/weekly-commentary">said</a> that they are positive about the AI theme in the technology sector. &#8220;Valuations for AI beneficiaries are supported as tech companies keep beating high earnings expectations. We think upbeat sentiment can broaden out,&#8221; their note said.
BlackRock also added that they see the AI buildout and adoption creating opportunities across sectors. &#8220;We get selective, moving toward beneficiaries outside the tech sector. Broad-based earnings growth and a quality tilt make us overweight U.S. stocks overall.&#8221;
Predicting how December could look like for the stock markets, Ryan Detrick, chief market strategist at Carson Group, highlighted how markets have performed better than average in December in every election year since 1950.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No month is more likely to be higher than December in an election year (83.3%). <a href="https://t.co/WrOI59tUiR">pic.twitter.com/WrOI59tUiR</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1861092399449284637?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data:
This week&#8217;s economic calendar is not as packed as last week&#8217;s due to Thanksgiving. Here are the key events lined up for Tuesday:
<ul>
<li>The S&amp;P Case-Shiller home price index for 20 cities will be released at 9 a.m. ET.</li>
<li>Data on consumer confidence and new home sales will be released at 10 a.m. ET.</li>
<li>The minutes of the Fed's November FOMC meeting will be released at 2 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Woodward Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is up by almost 11% in premarket trading after Pathstone Holdings LLC boosted its position by 28.6% during the 3rd quarter, as per SEC filing. The company also reported a record revenue of $3 billion in the September quarter, aided by the performance in both aerospace and industrial segments.</li>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rose 6% in premarket as it reacted to reports that Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reached a "conditional" settlement concerning a 2020 lawsuit. The Elon Musk-led company had accused Rivian of poaching Tesla employees to get ahold of its EV trade secrets.</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) was trading above 5.5% in premarket after the company advanced breast cancer care with the Oncotype DX test and genomic profiling research at the San Antonio Breast Cancer Symposium 2024.</li>
<li>Semtech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was up over 19% in premarket hours after the chipmaker reported a strong set of earnings. The company posted revenue of $236.8 million for the quarter with quarterly earnings of $0.26 per share as compared to $0.02 per share a year ago.</li>
<li>Blue Bird Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was down over 10% in premarket after its fourth-quarter earnings missed analyst estimates. The quarterly earnings of $0.77 per share missed the Zacks Consensus Estimate of $0.78 per share. This compares to the EPS of $0.66 in Q4 of the previous fiscal.</li>
<li>Investors are awaiting earnings results from Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.93% to hover around $69.57.
The 10-year Treasury note yield eased to 4.293%.
Major Asian markets ended lower on Tuesday, except for Hong Kong&#8217;s Hang Seng Index. European markets were also down in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo courtesy: Wikimedia

Economics

Federal Reserve

Pre-Market Outlook

BLBD

DELL

TSLA

US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks

The company said new data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally.

Exact Sciences To Present 10 Abstracts Demonstrating Breadth Of Its Precision Oncology Portfolio At SABCS

New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective
Modeling data estimate adding MCED testing to standard-of-care screening could reduce cancer mortality by 17%
New analysis from DETECT-A study supports MCED testing as a complement to current guideline-recommended screening
Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening may reduce the incidence of stage IV cancer and, subsequently, cancer mortality over 10 years. Another new analysis from the DETECT-A study suggests that adding MCED testing complements guideline-recommended lung cancer screening without affecting adherence to current standard of care. These findings will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in San Diego, Calif.

Exact Sciences Unveils Data Showing Multi-Cancer Early Detection At AACR Special Conference On Liquid Biopsy; New Evidence Shows Multi-Biomarker Class Approach Improved Cancer Detection, Including In Earlier Stages When Treatment May Be More Effective; Modeling Data Estimate Adding MCED Testing To Standard-Of-Care Screening Could Reduce Cancer Mortality By 17%

Insider Trades

Exact Sciences CEO Kevin Conroy Buys 19,500 Shares At $51.35 Each, Investing $1M; Now Holds 1.07M Direct Shares, With Total Holdings Reaching 1.41M Shares Plus 683K Options And Restricted Stock Units

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a price targ...

Craig-Hallum Sticks to Their Buy Rating for Exact Sciences (EXAS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NeoGenomics (NEO – Research Report), Exact Science...

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Exact Sciences (EXAS) and Exelixis (EXEL)

Bernstein analyst Eve Burstein maintained a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $70.00. The compa...

Exact Sciences (EXAS) Gets a Buy from Bernstein

Baron Discovery Fund Q4 2024 Shareholder Letter

Voya Small Cap Growth Strategy Q4 2024 Commentary

Artisan Mid Cap Fund Q4 2024 Commentary

The company states: "Exact Sciences (EXAS) shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical O...

Exact Sciences validates Oncodetect ability to detect molecular residual Disease

In a report released today, William Bonello from Craig-Hallum assigned a Buy rating to Exact Sciences (EXAS – Research Report). The company's share...

Exact Sciences (EXAS) Receives a Buy from Craig-Hallum

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Netflix upgraded, Electronic Arts downgraded: Wall Street's top analyst calls

Exact Sciences: Liquid Biopsy Threat Is Solidifying

AEIS

ALAB

AMZN

ANET

ARGX

ASGN

ASND

AXON

BCAP

BCUCF

BCUCY

BOOT

BROE

CDNA

CSGP

CWAN

CYBR

DKNG

EXEL

EXOD

GDDY

GOLF

GOOG

GTLB

GTLS

GWRE

HOOD

HUBB

INSM

INTA

KTOS

LLYVA

LLYVB

LLYVK

LOGI

MAGN

MNDY

MPWR

MRVL

MSFT

MTSI

NFLX

NTRA

ONTO

PACS

PLTR

PSTG

RDDT

REXR

ROAD

RVLV

SHOP

SPOT

TEAM

TTAN

USFD

VEEV

VOYA

VRNS

XRAY

Screenshot 2024-08-30 at 6.27.59 PM

MYNZ

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Screenshot 2024-06-04 at 5.31.42 PM

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Press Releases

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

Exact Sciences to Participate in November Investor Conference

Exact Sciences Announces Third-Quarter 2024 Results

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

Exact Sciences to Participate in December Investor Conferences

Exact Sciences to Participate in J.P. Morgan Healthcare Conference

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Comments

Exact Sciences

뉴스

에 대한 최신 뉴스 Exact Sciences (NASDAQ:EXAS) 주식

일요일, 12월 01, 2024

수요일, 11월 06, 2024

일요일, 9월 15, 2024

일요일, 8월 04, 2024

목요일, 8월 01, 2024

화요일, 6월 11, 2024

금요일, 6월 07, 2024

목요일, 5월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌